Trial Profile
A phase 1b/2a trial to investigate safety and efficacy of tesevatinib for the treatment of Autosomal Recessive Polycystic Kidney disease (ARPKD) in newborns
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2017
Price :
$35
*
At a glance
- Drugs Tesevatinib (Primary)
- Indications Autosomal recessive polycystic kidney disease
- Focus Adverse reactions; Therapeutic Use
- 03 Aug 2017 According to a Kadmon Corporation media release, the company expects to initiate this trial in third quarter of 2017.
- 22 Mar 2017 According to a Kadmon Corporation media release, the company anticipates to initiate this study in the second quarter of 2017.
- 19 Nov 2016 According to a Kadmon Corporation media release, the company anticipates to initiate this study in the year 2017.